Literature DB >> 17599942

Contraceptive failure rates in France: results from a population-based survey.

C Moreau1, J Trussell, G Rodriguez, N Bajos, J Bouyer.   

Abstract

BACKGROUND: Despite the widespread use of highly effective contraceptive methods in France, one in every three pregnancies is unintended, of which 65% occur while using contraceptives. In the USA, 49% of pregnancies are unintended, half of which result from contraceptive failure. This study provides estimates of method-specific failure rates among French women.
METHODS: We use data from the 2000 Cocon Study, a population-based cohort, comprising a representative sample of 1689 women aged 18-44 years who described their contraceptive history. Piecewise-constant hazards models were used to estimate method-specific contraceptive failure rates during the first 5 years of contraceptive use. A random effect was introduced to take into account the fact that some women contribute more than 1 contraceptive episode. These same models were used to assess the effects of socio-demographic characteristics on the probability of contraceptive failure among pill, intrauterine device (IUD) and condom users.
RESULTS: Overall, 2.9% of women experienced a contraceptive failure in the first year of use and 8.4% in the first 5 years of use. The IUD had the lowest first year failure rate (1.1%), followed by the pill (2.4%), the condom (3.6%), fertility awareness methods (periodic abstinence or safe period by temperature) (7.7%), withdrawal (10.1%) and spermicides (21.7%). These failure rates varied little by user characteristics.
CONCLUSIONS: Lower failure rates among French women compared with those reported for US women suggest differences in contraceptive practices which need to be further explored.

Entities:  

Mesh:

Year:  2007        PMID: 17599942     DOI: 10.1093/humrep/dem184

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  18 in total

1.  Anti-epileptic drugs and hormonal treatments.

Authors:  Clare A Johnston; Pamela M Crawford
Journal:  Curr Treat Options Neurol       Date:  2014-05       Impact factor: 3.598

2.  Estimates of unintended pregnancy rates over the last decade in France as a function of contraceptive behaviors.

Authors:  Caroline Moreau; Aline Bohet; James Trussell; Nathalie Bajos
Journal:  Contraception       Date:  2013-11-12       Impact factor: 3.375

3.  Contraceptive paths of adolescent women undergoing an abortion in France.

Authors:  Caroline Moreau; James Trussell; Nathalie Bajos
Journal:  J Adolesc Health       Date:  2011-10-07       Impact factor: 5.012

4.  Male experiences of unintended pregnancy: characteristics and prevalence.

Authors:  Anna Kågesten; Nathalie Bajos; Aline Bohet; Caroline Moreau
Journal:  Hum Reprod       Date:  2014-10-14       Impact factor: 6.918

5.  Patterns of contraceptive use before and after an abortion: results from a nationally representative survey of women undergoing an abortion in France.

Authors:  Caroline Moreau; James Trussell; Julie Desfreres; Nathalie Bajos
Journal:  Contraception       Date:  2010-04-21       Impact factor: 3.375

6.  Reducing unintended pregnancies: a microsimulation of contraceptive switching, discontinuation, and failure patterns in france.

Authors:  Nadia G Diamond-Smith; Caroline Moreau; David M Bishai
Journal:  Stud Fam Plann       Date:  2014-12

Review 7.  Progress and prospects in male hormonal contraception.

Authors:  John K Amory
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2008-06       Impact factor: 3.243

Review 8.  Beyond the Condom: Frontiers in Male Contraception.

Authors:  Mara Y Roth; John K Amory
Journal:  Semin Reprod Med       Date:  2016-03-04       Impact factor: 1.303

Review 9.  Male hormonal contraception.

Authors:  Mara Y Roth
Journal:  Virtual Mentor       Date:  2012-02-01

Review 10.  Male hormonal contraception: looking back and moving forward.

Authors:  M Y Roth; S T Page; W J Bremner
Journal:  Andrology       Date:  2015-10-09       Impact factor: 3.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.